Drug Profile
Research programme: Lafora disease therapeutics - Vyera Pharmaceuticals
Alternative Names: TUR 005Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Turing Pharmaceuticals
- Developer Vyera Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lafora disease
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Myoclonic-epilepsies in USA
- 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals
- 12 Nov 2015 Preclinical trials in Lafora disease in USA (unspecified route)